Even though wet AMD is routinely treated via anti-VEGF-A based therapy (Yazdi et al., 2015), this therapy can only delay the progress of the disease due to a lack of detailed understanding of how the proangiogenic factors are induced. This evidence concerns the gene VEGFA and wet macular degeneration.